Dipartimento di Biologia Molecolare, Università di Siena, Policlinico Le Scotte, II piano, V lotto, Viale Bracci 1, I-53100 Siena, Italy.
Antimicrob Agents Chemother. 2010 Aug;54(8):3197-204. doi: 10.1128/AAC.01336-09. Epub 2010 May 24.
Metallo-beta-lactamase (MBL)-producing bacteria are emerging worldwide and represent a formidable threat to the efficacy of relevant beta-lactams, including carbapenems, expanded-spectrum cephalosporins, and beta-lactamase inactivator/beta-lactam combinations. VIM-2 is currently the most widespread MBL and represents a primary target for MBL inhibitor research, the clinical need for which is expected to further increase in the future. Using a saturation mutagenesis approach, we probed the importance of four residues (Phe-61, Ala-64, Tyr-67, and Trp-87) located close to the VIM-2 active site and putatively relevant to the enzyme activity based on structural knowledge of the enzyme and on structure-activity relationships of the subclass B1 MBLs. The ampicillin MIC values shown by the various mutants were affected very differently depending on the randomized amino acid position. Position 64 appeared to be rather tolerant to substitution, and kinetic studies showed that the A64W mutation did not significantly affect substrate hydrolysis or binding, representing an important difference from IMP-type enzymes. Phe-61 and Tyr-67 could be replaced with several amino acids without the ampicillin MIC being significantly affected, but in contrast, Trp-87 was found to be critical for ampicillin resistance. Further kinetic and biochemical analyses of W87A and W87F variants showed that this residue is apparently important for the structure and proper folding of the enzyme but, surprisingly, not for its catalytic activity. These data support the critical role of residue 87 in the stability and folding of VIM-2 and might have strong implications for MBL inhibitor design, as this residue would represent an ideal target for interaction with small molecules.
金属β-内酰胺酶(MBL)产生菌在全球范围内不断出现,对相关β-内酰胺类药物(包括碳青霉烯类、扩展谱头孢菌素类和β-内酰胺酶抑制剂/β-内酰胺类联合制剂)的疗效构成了严重威胁。VIM-2 是目前最为广泛流行的 MBL,也是 MBL 抑制剂研究的主要靶标,预计未来对 MBL 抑制剂的临床需求将会进一步增加。本研究采用饱和突变技术,针对紧邻 VIM-2 活性中心且根据该酶结构知识和亚类 B1 MBLs 的结构-活性关系推测与酶活性相关的四个残基(Phe-61、Ala-64、Tyr-67 和 Trp-87)的重要性进行了探究。根据各种突变体的氨苄青霉素 MIC 值,随机氨基酸位置对突变体的影响差异非常大。64 位似乎对取代具有较强的耐受性,动力学研究表明,A64W 突变并未显著影响底物水解或结合,这与 IMP 型酶有很大不同。Phe-61 和 Tyr-67 可以被多种氨基酸取代,而氨苄青霉素 MIC 值不受显著影响,但相比之下,Trp-87 对氨苄青霉素耐药性至关重要。对 W87A 和 W87F 变体的进一步动力学和生化分析表明,该残基显然对酶的结构和正确折叠很重要,但令人惊讶的是,对其催化活性没有影响。这些数据支持了 87 位残基在 VIM-2 稳定性和折叠中的关键作用,并且可能对 MBL 抑制剂设计具有重要意义,因为该残基将成为与小分子相互作用的理想靶标。